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Abstract
Nearly all DNA polymerases require processivity factors to ensure continuous incorporation of
nucleotides. Processivity factors are specific for their cognate DNA polymerases. For this reason, the
vaccinia DNA polymerase (E9) and the proteins associated with processivity (A20 and D4) are excellent
therapeutic targets. In this study, we show the utility of stepwise rapid plate assays that i) screen for
compounds that block vaccinia DNA synthesis, ii) eliminate trivial inhibitors, e.g. DNA intercalators, and
iii) distinguish whether inhibitors are specific for blocking DNA polymerase activity or processivity. The
sequential plate screening of 2,222 compounds from the NCI Diversity Set library yielded a DNA
polymerase inhibitor (NSC 55636) and a processivity inhibitor (NSC 123526) that were capable of
reducing vaccinia viral plaques with minimal cellular cytotoxicity. These compounds are predicted to
block cellular infection by the smallpox virus, variola, based on the very high sequence identity between
A20, D4 and E9 of vaccinia and the corresponding proteins of variola.
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Abstract
Nearly all DNA polymerases require processivity factors to ensure continuous incorporation of
nucleotides. Processivity factors are specific for their cognate DNA polymerases. For this reason,
the vaccinia DNA polymerase (E9) and the proteins associated with processivity (A20 and D4) are
excellent therapeutic targets. In this study, we show the utility of stepwise rapid plate assays that i)
screen for compounds that block vaccinia DNA synthesis, ii) eliminate trivial inhibitors, e.g. DNA
intercalators, and iii) distinguish whether inhibitors are specific for blocking DNA polymerase
activity or processivity. The sequential plate screening of 2,222 compounds from the NCI
Diversity Set library yielded a DNA polymerase inhibitor (NSC 55636) and a processivity
inhibitor (NSC 123526) that were capable of reducing vaccinia viral plaques with minimal cellular
cytotoxicity. These compounds are predicted to block cellular infection by the smallpox virus,
variola, based on the very high sequence identity between A20, D4 and E9 of vaccinia and the
corresponding proteins of variola.
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1. Introduction
The Centers for Disease Control has designated the smallpox virus, variola, as a class A
agent of bioterrorism (Lane et al., 2001). Smallpox was globally eradicated in 1980 by
vaccination with vaccinia virus. Currently, however, much of the human population is at risk
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since the vaccine has been discontinued. Moreover, the vaccine is contraindicated for the
considerable portion of the population that is immunologically compromised (Lane and
Millar, 1971; Lane et al., 1969; 1970). Therapeutics can protect these populations and serve
as a rapid response to [MSOffice1]a smallpox outbreak.
New anti-poxvirus agents have recently emerged in the field, targeting the different points of
the viral life cycle. Novel and promising agents include neutralizing antibodies that inhibit
virus entry (Chen et al., 2006); nucleoside analogs such as cidofovir and ribavirin that
terminate DNA replication upon incorporation into the growing DNA strand (Magee et al.,
2005) or RNA transcript (Bougie and Bisaillon, 2004); ST-246 that targets the envelope
protein production (Quenelle et al., 2007a; Yang et al., 2005) and Gleevec that blocks the
tyrosine kinase activity (Reeves et al., 2005) required for motility, preventing the release of
the extracellular enveloped virus (EEV). At present, cidofovir and ST-246 are the most
effective therapeutics against poxvirus infection (De Clercq, 2002; Quenelle et al., 2007a;
Sbrana et al., 2007).
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The emergence and characterization of drug-resistant viruses (Beadle et al., 2002; Wodarz
and Lloyd, 2004) including cidofovir-resistant poxviruses (Andrei et al., 2006; Kornbluth et
al., 2006; Robbins et al., 2005; Smee et al., 2002) makes it compelling to discover new
antiviral compounds. Additionally, therapeutics directed against a multiplicity of targets will
further alleviate the problem of drug resistance. Indeed, synergistic inhibitory effect against
vaccinia and cowpox viruses was recently demonstrated in vitro by combining ST-246 with
hexadecyloxypropyl-cidofovir, CMX001, a derivative of cidofovir with increased
bioavailability (Quenelle et Almost., 2007b).
The poxvirus replication cycle occurs entirely within the cytoplasm. The 192-kilobase
vaccinia genome provides a multitude of potential targets that play distinct roles in vaccinia
replication. The vaccinia proteins involved in DNA synthesis include a DNA polymerase
(E9), nucleoside triphosphatase (D5), protein kinase (B1), putative DNA polymerase
processivity factor (A20), uracil DNA glycosylase (D4), Holliday junction endonuclease
(A22), DNA topoisomerase (H7), single-stranded DNA binding protein (I3), DNA ligase
(A50), and enzymes involved in precursor metabolism, namely thymidine kinase (J2),
thymidylate kinase (A48), ribonucleotide reductase (F4, I4) and dUTPase (F2) (Beaud,
1995; Moss, 2001).
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An excellent target for therapeutics is the processivity complex. Almost all DNA
polymerases from bacteriophages to mammals require processivity factors that enable them
to replicate extended strands (Jeruzalmi et al., 2002; Kuriyan and O’Donnell, 1993).
Processivity factors ensure that the rate of nucleotide incorporation by the DNA polymerase
exceeds the rate of its dissociation from the template (Hingorani and O’Donnell, 2000;
Weisshart et al., 1999). When the E9 DNA polymerase of vaccinia virus is presented alone
to a DNA primer-template, it can incorporate approximately ten nucleotides (McDonald and
Traktman, 1994). However, E9 complexed with processivity-associated proteins A20 and
D4 incorporates thousands of nucleotides into the nascent DNA strand. Importantly, since
A20, D4 and E9 vaccinia proteins share 98% sequence identity to the corresponding proteins
of variola, they are excellent antiviral targets to prevent an outbreak of smallpox.
It is still unclear how A20 and D4 collaborate to enable E9 to synthesize DNA processively
under physiological conditions. Through the use of recombinant virus and coimmunoprecipitation studies, A20 was shown to physically interact with E9 (Klemperer et
al., 2001). Significantly, A20 has been shown to interact with D4 in vitro and by yeast-two
hybrid assays (Ishii and Moss, 2002; McCraith et al., 2000; Stanitsa et al., 2006). On the
other hand, D4 belongs to uracil DNA glycosylase (UDG) family (Scaramozzino et al.,
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2003), a class of enzymes which initiates the base excision and DNA repair pathway for
misincorporated uracil through cleavage of the glycosidic bond. While D4 is required for
vaccinia DNA replication (Millns et al., 1994), mutations of the D4 conserved catalytic
region abolished the glycosylase activity but did not prevent viral DNA replication (De Silva
and Moss, 2003; Ellison et al., 1996). Crystal structure of D4 recently revealed the possible
formation of a tetrameric structure which consequently suggests its role as the sliding clamp
associated with E9 DNA polymerase (Schormann et al., 2007). This model further implies
the role of A20 as a scaffold for E9, D4 and possibly other replication proteins. Thus,
desirable therapeutics include those that disrupt the interactions in the A20, D4 and E9
complex.
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We have developed a rapid plate assay (Lin and Ricciardi, 2000) as a means of identifying
novel antiviral therapeutics with lower toxicity. Previously, we used this assay to identify
the promising compound, NSC 373989, that inhibits Kaposi’s sarcoma-associated herpes
virus (KSHV) processive DNA synthesis in vitro and blocks lytic KSHV infection
(Dorjsuren et al., 2006). In this study, we screened for potential therapeutics that block DNA
synthesis of vaccinia virus. The experimental design employed a stepwise approach that
subjects compounds to a series of distinct and increasingly stringent criteria to identify both
polymerase and processivity inhibitors of vaccinia DNA synthesis. From a screen of 2,222
compounds, we identified both a polymerase inhibitor and a processivity inhibitor that block
vaccinia DNA synthesis and viral infection. These inhibitory compounds have therapeutic
potential due to their low cellular cytotoxicity.

2. Materials and Methods
2.1 Compound library
The NCI Training and Diversity Set libraries were obtained from the Drug Synthesis and
Chemistry Branch, Developmental Therapeutics Program, National Cancer Institute
(http://dtp.nci.nih.gov/). The Training Set contains 230 anti-cancer compounds that are
frequently used to confirm the reproducibility of high throughput screening assays
(Shoemaker et al., 2002). The Diversity Set comprises 1,992 compounds selected from
approximately 140,000 compounds using the Chem-X program (Accelrys, San Diego, CA).
These compounds represent diversity in terms of three-dimensional pharmacophores
(http://dtp.nci.nih.gov/branchers/dscb/diversity_explanation.html).
2.2 In vitro translated proteins and vaccinia virus-infected cytoplasmic lysate
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Vaccinia virus polymerase (E9), A20 and UDG (D4) proteins were expressed from
pcDNA3.2/v5 (Invitrogen) in vitro using Promega TNT T7 coupled transcription/translation
system. KSHV DNA polymerase-8 (Pol8) and processivity factor-8 (PF8) were translated in
vitro from pTM1-Pol8 and pTM1-PF8, respectively (Lin et al., 1998). To confirm
expression, an aliquot of the translation reactions was labeled with [35S]-methionine,
fractionated on an SDS-10% polyacrylamide gel, and visualized by autoradiography.
Throughout the study, a thymidine kinase (TK) deficient WR strain vaccinia virus was used
to infect monolayers of BSC-1 cells. This virus was kindly provided by Drs. G. Cohen and
R. Eisenberg. The vaccinia virus-infected cell lysate was prepared according to previously
described methods (Kit et al., 1962). Briefly, the cells were infected at a multiplicity of
infection (MOI) of 15. The vaccinia-infected cells were incubated at 37 °C for 6 h in the
presence of hydroxyurea. The cells were harvested by scraping then pelleting at 500 rpm.
The pellet was washed with phosphate-buffered saline (PBS) followed by hypotonic buffer
(10 mM Hepes, 1.5 nM MgCl2, 10 mM KCl). After resuspension in hypotonic buffer, the
cells were Dounce-homogenized and centrifuged at 15,000 rpm for 30 min. The suspension
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was passed through a 2 micron filter to remove the viral cores and nuclear particles. The
vaccinia-infected cytoplasmic lysate was stored in -80 °C in the presence of 20% glycerol.
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2.3 High-throughput screening for inhibitors of DNA synthesis using the rapid plate assay
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A rapid plate DNA synthesis assay (Lin and Ricciardi, 2000) was performed using vacciniainfected cell lysate. A 1.2:1 ratio of a 20-mer oligonucleotide primer (5!GCGAATGAATGACCGCTGAC-3!) and a 5!-end biotinylated 100-mer oligonucleotide
template (5!- Biotin — GCACTTATTGCATTCGCTAGTCCACCTTGGATCTCAGGCT
ATTCGTAGCGAGCTACGCGTACGTTAGCTTCGGTCATCCCGTCAGCGGTCATT
CATTGGC — 3!) were heated at 90 °C for 5 min and annealed by gradual cooling to room
temperature. The annealed primer-template (P/T) was diluted with PBS to a concentration of
10 pmol/"L. The 96-well microtiter streptavidin-coated plates (Streptawell plates, Roche
Applied Science, Indianapolis, IN) were coated with 5 pmol/well of the P/T solution and
incubated at 37 °C for 90 min. The wells were washed with 100 "L PBS. Control (DMSO,
acyclovir, azidothymidine (AZT) and ethylenediamine tetracetic acid (EDTA)) and test
compounds were individually added to the wells to a final concentration of 167 "M. The 60
"L DNA synthesis reaction mixture contained 100 mM (NH4)2SO4, 20 mM Tris-HCl pH
7.4, 3 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 2% glycerol, 40 ug/mL BSA, 5 uM
dNTPs, 1 uM digoxigenin-11-2!-deoxyuridine-5!-triphosphate (DIG-dUTP, Roche Applied
Science) and 1 "L vaccinia lysate. The plates were incubated at 37 °C for 30 min. DNA
synthesis was determined by quantitating incorporation of DIG-dUTP using a DIG detection
ELISA kit (Roche Applied Science) using anti-digoxigenin-peroxidase (anti-DIG-POD) and
its substrate 2, 2!-azino-bis(3-ethylbenzthiazoline)-sulfonate (ABTS), and by measuring the
absorbance at 405 nm on a microplate reader (Tecan Genious Pro, Grodig, Austria). The
inhibitory threshold was set at 50%.
2.4 Screen to eliminate trivial inhibitors
The selectivity screen was used to eliminate non-specific inhibitors of vaccinia DNA
synthesis. A microplate assay was employed in which DNA synthesis was directed by
KSHV Pol8/PF8 as previously described (Dorjsuren et al., 2006; Lin and Ricciardi, 2000).
2.5 Polymerase vs. processivity inhibition
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Two different plate assays were used to distinguish polymerase versus processivity
inhibitors. For the polymerase plate assay, dA was distributed in the template such that the
DIG epitope could be uniformly incorporated throughout the newly synthesized strand. The
DNA synthesis reaction was performed using a low salt buffer (20 mM Tris-HCl pH 7.4, 3
mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, and 2 % glycerol) and 1 "L in vitro translated
polymerase enzyme E9. For the processivity plate assay, a biotinylated primer/template (5!GCCAATGAATGACCGCTGAC -3!) / (5!- Biotin —
AGCACTATTGACATTACAGAGTCGCCTTGGCTCTCTGGCTGTTCGTTGCGGGC
TCCGCGTGCGTTGGCTTCGGTCGTCCCGTCAGCGGTCATTCATTGGC — 3!) was
designed so that the DIG epitope would be incorporated only at the distal end of the
template. The processivity plate assay was conducted using a high salt buffer (100 mM
(NH4)2SO4, 20 mM Tris-HCl pH 7.4, 3 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 2 %
glycerol), to which one microliter each of the in vitro translated proteins A20, D4, and E9
was added in each well. All inhibitors were tested at a final concentration of 167 "M.
2.6 M13 DNA synthesis
In vitro DNA synthesis using an M13-primed template was performed with slight
modifications as described (Klemperer et al., 2001; Lin and Ricciardi, 1998). Briefly, the
DNA synthesis reaction mixtures (25 "L final volume), contained 10 mM Tris-HCl (pH
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7.5), 40 mg/mL of BSA, 4% glycerol, 0.1 mM EDTA, 5 mM dithiothreitol (DTT), 8 mM
MgCl2, 20 fmol of primed M13mp18 single-stranded (ss) DNA, 750 ng of E. coli SSB, 60
"M each dGTP, dTTP and dATP, and 20 "M [#-32P]dCTP. The mixtures were preincubated with 1 "L each of A20, D4 and E9 at 30 °C for 3 min and the reactions were
initiated by the addition of radiolabeled dCTP, incubated for 30 min and stopped with an
equal volume of 1% SDS-40 mM EDTA. The reaction products were fractionated on a 0.8%
non-denaturing agarose gel at 60V and analyzed by a PhosphorImager (Amersham
Biosciences).
2.7 Plaque reduction assay
African green monkey kidney BSC-1 cells (ATCC) were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco BRL
Life Technologies, Gaithersburg, MD) and 0.1% gentamicin antibiotic, at 37 °C in a
humidified 5% CO2 environment. BSC-1 cells were infected in 48-well plates at an MOI of
0.001 with the WR strain of vaccinia virus. One hour post-infection, 400 "L of DNA
synthesis inhibitors, ranging from 200 mM to 200 "M, were added per well and incubated at
37 °C overnight. All inhibitor and control compounds were dissolved in DMSO and diluted
with DMEM. A 5% solution of formaldehyde in PBS was used to fix the cells. After
washing twice with PBS, the plate was stained with 0.2% crystal violet in 50% ethanol.
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For HSV-2, a black plaque assay, which enhances the sensitivity of viewing plaques, was
performed under similar conditions as for the vaccinia plaque reduction assay. Confluent
monolayers were infected with HSV-2 (MOI = 0.001) for 1 h. The inhibitors (200 nM to 200
"M) were added one hour post-infection, and incubated at 37 °C overnight. The wells were
washed with PBS, fixed with 2:1 methanol/acetone for 1 h and dried completely. HSV antigB, gD and gC antibodies were added and incubated for two hours at RT. The wells were
washed twice with PBS and analyzed by immunoperoxidase staining. Both plaque assays
were performed in triplicate in at least three independent experiments.
2.8 Cytotoxicity assay
BSC-1 cells were grown to confluency in white 96-well plates at 37 °C in DMEM
containing 10% FBS and 0.1% gentamicin in the presence or absence of inhibitor.
Cytotoxicity of the inhibitors (200 nM — 200 "M) was assayed using the aCella-TOX
bioluminescence cytotoxicity kit (Cell Technology Inc., Mountain View, CA) to follow the
release of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). As a positive control, cells
were completely lysed to cause maximum release of GAPDH. At least three independent
assays were performed in triplicate for reproducibility testing.
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2.9 Therapeutic Index (TI)
For each compound, the concentration of inhibitor needed to produce half maximal cell
cytotoxicity (CC50) and to reduce 50% of the plaques (IC50) was determined. The
therapeutics index was established as the ratio of the CC50 to IC50.
3.0 Compound confirmation
The molecular weights of the hit compounds were confirmed using low resolution liquid
chromatography/mass spectrometry, electrospray ionization mode (ES+, Micromass LC,
Opus software system, Department of Chemistry, University of Pennsylvania).
3.1 Preliminary evaluation of analogs
Analogs of the parental inhibitors (hit) compounds listed in Table 1 were obtained through
bioinformatics compound mining. This was accomplished by performing structural
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similarity searches using the Bit Vector Structural Map online
(http://spheroid.ncifcrf.gov/spheroid/) developed by the Developmental Therapeutic
Program of the National Cancer Institute to aid in drug discovery.

3. Results
The rapid plate assay was initially used in a primary screen that led to the identification of
an inhibitor of KSHV processive DNA synthesis (Dorjsuren et al., 2006). In this study, we
expanded the utility of the rapid plate assay by incorporating sequential steps to select for
inhibitors that block vaccinia virus DNA synthesis. A flowchart depicting the stepwise
screening protocol is presented in Figure 1.
Step I. Primary high-throughput screen
For this study, the rapid plate assay was performed in a microtiter plate in which a 5!biotinylated template was immobilized onto streptavidin-coated wells. In the presence of
vaccinia lysate proteins, four dNTPs as well as digoxigenin-dUTP were incorporated. A
peroxidase-conjugated anti-digoxigenin antibody generated a colorimetric reaction that was
read at 405 nm.
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We used the rapid plate assay to screen the NCI Diversity and Training Set library of 2,222
compounds. This library contains diverse three-dimensional structures representative of
approximately 140,000 compounds from the NCI-DTP library. For each compound of the
diversity set, 1 "L was added to the reaction mix resulting in a final concentration 167 "M.
It is noted that we used a thymidine kinase (TK) deficient vaccinia virus (derived from WR
strain) in order to disfavor obtaining nucleoside inhibitors that require phosphorylation. As
negative controls we used AZT and acyclovir, which do not inhibit vaccinia virus (Holzer et
al., 2005; St. Clair et al., 1980). A total of 169 compounds decreased DNA synthesis by 50%
or greater, giving a hit rate of 7.6% (Figure 2).
Step II. Screen to eliminate trivial inhibitors
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We next tested the 169 hit compounds obtained from the primary screen (Step I) to
determine if these vaccinia inhibitors were also able to block DNA synthesis conducted by a
DNA polymerase and processivity complex from a different virus. Unlike vaccinia which
requires three proteins for processive DNA synthesis, KSHV relies on only two proteins, a
DNA polymerase (Pol8) and processivity factor (PF8) (Chen et al., 2004,2005;Lin et al.,
1998). Compounds (at a concentration of 167 "M) that block DNA synthesis of both
vaccinia virus and KSHV could, as one reason, be acting as trivial inhibitors, e.g. by
intercalating DNA, and therefore were not pursued. The result of this step yielded 47
compounds, giving a hit rate of 2.1% from Step I (2,222 compounds) (Figure 3).
Step III. Screen to distinguish polymerase vs. processivity inhibitors
We individually synthesized the vaccinia A20, D4, E9 proteins in vitro in order to
distinguish inhibitors that target nucleotide incorporation by E9 alone from inhibitors that
target processive incorporation by the triad, A20, D4 and E9. These translated proteins were
analyzed in two distinct plate assays.
To define polymerase inhibitors, E9 activity was conducted in low salt, in which DNA
polymerases are able to synthesize fully extended strands in the absence of processivity
factors (Chaudhuri and Parris, 2002; Williams et al., 1993). DNA synthesis by E9 was tested
on a uniform template, which contains evenly distributed sites for DIG-dU incorporation
(Figure 4A). Two compounds (69343 and 55636) were designated as polymerase inhibitors
since they prevented E9 from incorporating nucleotides on the uniform template (Figure
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4B). As expected, these polymerase inhibitors also blocked incorporation on the distal
template (Figure 4D).
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To define processivity inhibitors, high salt was used which limits nucleotide incorporation
by E9 alone but allows processive DNA synthesis by the A20, D4, E9 triad to occur. For the
processivity assay, a distal template was used in which DIG-dU is incorporated only at the 3!
end of the nascent DNA by virtue of dA being positioned solely at the 5! end of the template
(Figure 4C). Two compounds (123526 and 124808) were designated as processivity
inhibitors since they only prevented DNA synthesis by the triad on the distal template
(Figure 4D) but not by E9 on the uniform template (Figure 4B).
It is noted that of the 47 compounds that passed Step II, 43 compounds did not prove
inhibitory in either the vaccinia polymerase or processivity assay. The use of infected cell
lysate in Step I vs. in vitro translated proteins in Step III may account for this difference. We
have in fact noted the ability of in vitro translated proteins to support a more robust DNA
synthesis as opposed to infected cell lysates (data not shown). Another reason could be due
to a possible difference in sensitivity between KSHV vs. vaccinia proteins. Regardless, four
compounds emerged from these sequential steps (I — III) that involved passing a rigorous
screen employing different protein sources and viral systems.
Step IV. M13 DNA Synthesis Assay
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The ability of compounds to inhibit DNA synthesis in the rapid plate assay was confirmed
using the M13 DNA synthesis assay. In the M13 assay, full-length DNA strands of 7,249
nucleotides are produced and visualized by autoradiography. Because the length of the M13
product is extensive, this assay serves as a rigorous test for processive DNA synthesis. As
shown in Figure 5, lane 2, full-length double stranded M13 DNA was successfully
synthesized in the presence of the A20, D4, E9 triad. The brackets shown in Figure 5
indicate the typical formation of greater than unit length products (Hamilton et al.,
2007;Willer et al., 1999;Zhang and Evans, 1993). The synthesis of M13 DNA was blocked
by increasing concentrations of the two polymerase inhibitors, NSC 69343 (lanes 3-7) and
NSC 55636 (lanes 8-12), and the two processivity inhibitors, NSC 123526 (lanes 13-17) and
NSC 124808 (lanes 18-22). Most notably, the polymerase inhibitor NSC 69343 completely
inhibited M13 DNA synthesis at 100 "M (lane 6). All of the other compounds inhibited at a
concentration between 100 "M and 1 mM.
Step V. Plaque reduction assays

NIH-PA Author Manuscript

A plaque reduction assay was used to evaluate the antiviral activity of the two polymerase
and the two processivity inhibitors that were selected from Step III. For comparison, we also
performed plaque reduction assays on HSV-2. The results are summarized in Table I.
Surprisingly, NSC 69343, the more potent polymerase inhibitor based on in vitro assays,
was less remarkable in its ability to reduce vaccinia viral plaques when compared to NSC
55636, the less potent polymerase inhibitor. Interestingly, NSC 69343 was more effective in
inhibiting HSV-2 plaques than vaccinia plaques whereas NSC 55636 was equally effective
in inhibiting both viruses. With respect to the two processivity inhibitors, NSC 123526 was
significantly more effective than NSC 124808 in inhibiting vaccinia virus. However, both of
these processivity inhibitors were comparable in their abilities to block HSV-2. Overall,
NSC 55636 was the strongest viral inhibitor.
Step VI. Cytotoxicity assay
Cytotoxicity of the four inhibitors of vaccinia DNA synthesis was determined using the
aCella-TOX assay. This assay quantifies the cellular release of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), which is essential for the production of ATP in the glycolysis
Antiviral Res. Author manuscript; available in PMC 2011 August 14.
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pathway. GAPDH released into the cell media is used in a coupled reaction to generate ATP,
which is detected by luciferase/luciferin bioluminescence. As indicated in Table I, all of the
inhibitors had CC50 of greater than 200 "M in BSC-1 cells based on GAPDH release.
Cellular therapeutic indices for polymerase inhibitor NSC 55636 and
processivity inhibitor NSC 123526—The polymerase inhibitor NSC 55636 and
processivity inhibitor NSC 123526 were considered to be the most significant compounds
based on their efficacy at reducing vaccinia virus plaques with the least cytotoxicity. NSC
55636 gave a plaque reduction IC50 of 5.7 "M and CC50 of greater than 200 "M, resulting in
a cellular TI of greater than 40. NSC 123526 gave a plaque reduction IC50 of 47.5 "M and
CC50 of greater than 200 "M, resulting in a cellular TI of greater than four.
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Evaluation of analogs of polymerase and processivity inhibitors—Bioinformatic
mining of[MSOffice2] the four inhibitors listed in Table I generated 118 compounds that
were similar in structure, spatial conformation (3D), and chemical properties. Each of these
compounds was subjected to the stepwise screening procedure. Two compounds related to
NSC 55636 and one compound related to NSC 69343 emerged as hits (Figure 6). The two
NSC 55636 analogs (NSC 646023 and 406932) had similar IC50 values in the vaccinia
plaque assays (7.5 "M and 6.6 "M, respectively). By contrast, the NSC 69343 analog (NSC
159628) had an IC50 value (1.6 "M) that was dramatically improved over that of the
parental compound NSC 69343 (IC50 > 200).

4. Discussion
The availability of effective new therapeutics against variola virus, the causative agent of
smallpox, is essential to combat a potential smallpox outbreak. Vaccinia, a prototypic
member of the poxviridae family, serves as an ideal model for variola, as these two viruses
exhibit a high degree of genomic sequence identity (Afonso et al., 2002). For the purpose of
identifying new therapeutics against smallpox, we screened for compounds that target the
polymerase and processivity complex of vaccinia virus. We reasoned that compounds that
target the DNA synthesis proteins of vaccinia would likely target the corresponding proteins
of variola.
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In order to identify inhibitors of the polymerase/processivity complex, we utilized a
sequence of rapid plate assays. The first screening step selects for functional inhibitors that
block vaccinia DNA synthesis. This step, which uses infected cell lysate, was designed for
poxviruses, which are unique amongst the DNA viruses in that they replicate in the
cytoplasm. This provides a great advantage since there are no competing nuclear
polymerases in the cytoplasmic lysate that could contribute to anomalous results. The
second screening step ideally eliminates trivial inhibitors, e.g. DNA intercalators and DNA
groove binders. The third screening step distinguishes whether inhibition of the polymerase
or processive mechanism is targeted. Interestingly, this step could be applied to defining
inhibitors of other viruses and eukaryotes that engage processivity complexes in their DNA
synthesis.
Our screening method identified four compounds that inhibit vaccinia DNA synthesis. NSC
55636 and NSC 69343 prevented the catalytic activity of E9 DNA polymerase. By contrast,
NSC 123526 and NSC 124808 inhibited the processive activity of the triad A20, D4 and E9.
NSC 55636 (Fentichlor)
Despite the fact that NSC 69343 is a more potent inhibitor of E9 in the rapid plate assay, it
did not reduce vaccinia plaques efficiently. On the other hand, the compound of greatest
interest is NSC 55636, which reduced vaccinia plaques at a lower IC50 (5.7 "M) in the rapid
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plate assay. This polymerase inhibitor is also known as Fentichlor, an antibacterial,
anthelmintic and antifungal agent (Hugo and Bloomfield, 1971a,b,c;Watson, 1973) that has
been used as an additive in cosmetic products (Schmahl and Hieke, 1980;Schmahl and
Matissek, 1981). However, due to its photoallergenic nature, the use of Fentichlor in recent
years seems to be limited to agrochemicals. Specifically, Fentichlor has been shown to
undergo photodehalogenation generating aryl radicals (Delahanty et al., 1989;Li and
Chignell, 1987) and byproducts that may act as antigens (Hindsén et al., 2006).
Nevertheless, Fentichlor was reported to have no detectable teratogenic effects in pregnant
rats that received Fentichlor intragastrically (Veselova et al., 1980), and the Ames test has
shown that it is non-mutagenic (Serafimova et al., 2007). Interestingly, in silico modeling
suggested that Fentichlor is inactive against HIV-1 integrase, protease, reverse transcriptase
and virus uncoating (Vilar et al., 2006) (See supporting information in this reference).
In this study, we determined that Fentichlor inhibits the vaccinia viral DNA polymerases.
Furthermore, we found that Fentichlor is similarly effective in reducing plaques in both
HSV-2 and vaccinia-infected BSC-1 cells. Possibly, Fentichlor interacts with structural
motifs common to the DNA polymerases of both viruses.
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Fentichlor’s high cellular therapeutic index of greater than forty against vaccinia reflects its
ability to effectively block vaccinia infection with minimal cytotoxicity. The potency of this
compound is also reiterated by its analogs (NSC 406932 and NSC 646023). Our studies
indicate that Fentichlor is a potent antipoxvirus candidate and that analogs which do not
cause photosensitization should be pursued.
NSC 123526
Little is known about the processivity inhibitor NSC 123526, an S-fluorenylcysteine
compound. Since NSC 123526 does not inhibit E9 polymerase activity, it is interesting to
speculate that it perturbs the interactions of A20 and D4 with E9 to prevent continuous DNA
strand synthesis. Interestingly, a structurally related compound, S-trityl-L-cysteine, is a
potent tumor growth inhibitor of human Eg5 (Brier et al., 2004; Skoufias et al., 2006). The
cysteine moiety of S-trityl-L-cysteine renders the compound cell permeable and likely
delivers the flourenyl group to the interaction site, inducing local conformational changes. In
a study of S-tritylcysteine-related compounds, NSC 123526 was found to be non-toxic on
the leukemia cell line L-1210 (Zee-Cheng and Cheng, 1970). In our study, NSC 123526 had
a cellular therapeutic index of greater than four, making it a modest antipoxvirus agent.
NSC 69343 and NSC 124808
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This study yielded two other compounds, NSC 69343 and NSC 124808, that were effective
in blocking vaccinia DNA synthesis in the in vitro rapid plate assays but were not as
effective in blocking vaccinia infection. This was not due to poor cellular uptake, as these
two compounds were able to reduce HSV-2 plaques. It remains to be determined whether
these two inhibitors function by different mechanisms in inhibiting vaccinia and HSV-2.
The polymerase inhibitor NSC 69343 is in fact tetracycline, an antibiotic that inhibits the
prokaryotic 30S ribosome. It is thus fascinating that tetracycline can inhibit vaccinia DNA
synthesis. Our preliminary studies show that a more complex tetracycline-related compound,
viridicatumtoxin, had a greater inhibitory activity (IC50 = 1.6 "M) than all parental hits and
analogs.

SUMMARY
Our pilot screen of 2,222 compounds yielded two compounds, NSC 55636 and NSC
123526, which effectively block vaccinia virus DNA synthesis and infection. Future
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experiments will determine whether chemical modification of these compounds will further
improve their antiviral potency. Based on our stepwise approach, it is anticipated that an
expanded high throughput screen will identify additional new antiviral compounds that
inhibit poxvirus DNA synthesis.
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Figure 1.

Flowchart of stepwise screening protocol to identify inhibitors of vaccinia virus DNA
synthesis. The two most effective compounds targeted the DNA polymerase and
processivity activity, respectively.
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Figure 2.

A representative primary rapid plate assay. Compounds that inhibited DNA synthesis by
more than 50% are indicated by solid bars, and those that inhibit DNA synthesis by less than
50% are indicated by shaded bars. Indicated are wells with the positive (+) control inhibitor
EDTA (E) in duplicate and the negative (-) control inhibitors: unphosphorylated AZT (Z),
unphosphorylated acyclovir (A), DMSO alone (D) and no compound added (N).
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Figure 3.

Assay to eliminate trivial inhibitors. Hit compounds from the primary screen using vaccinia
lysates were futher tested in a KSHV rapid plate assay for their abilities to inhibit DNA
synthesis directed by Pol8/PF8. Compounds that inhibited Pol8/PF8 DNA synthesis (solid
bars) were categorized as potentially trivial inhibitors. Compounds that failed to block Pol8/
PF8 DNA synthesis (shaded bars) were considered to be bona fide inhibitors of vaccinia
DNA synthesis. Indicated are wells with the positive (+) control inhibitor EDTA (E) in
duplicate and the negative (-) control inhibitor DMSO alone (D) and no compound added
(N).
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Figure 4.

Assay to distinguish polymerase and processive inhibitors of vaccinia DNA synthesis. (A)
The model depicts the uniform incorporation of the DIG-dU on a template by E9
polymerase under low salt conditions. Under low salt conditions, E9 incorporates dNTPs
along the DNA template. (B) NCI hit compounds were analyzed on the uniform tempate in
the presence of E9 alone under low salt conditions to identify polymerase inhibitors. (C) The
model depicts incorporation of the label DIG-dUTP on the distal end of the template by the
triad (A20, D4, E9) under high salt conditions. This template was designed with all the
adenines near the biotinylated end to direct incorporation of the DIG label towards the 3! of
the growing strand. Under high salt conditions, E9 requires A20 and D4 to accomplish
processive DNA synthesis. (D) NCI hit compounds were analyzed on the distal tempate in
the presence of the A20, D4 and E9 triad under high salt conditions to identify processivity
inhibitors. Compounds that block E9 polymerase activity also blocked processivity. For both
A and C, the template 5! end is biotinylated for attachment to the streptavidin-coated plates.
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Figure 5.

Confirmation of inhibitors using the M13 DNA synthesis assay. Full-length ds DNA
products labeled with [#-32P]dCTP were synthesized from the M13 DNA primer/template in
the presence of the vaccinia triad (A20, D4, E9) and examined on a non-denaturing gel. The
ability of each polymerase and processivity inhibitor to block the M13 DNA synthesis was
examined by adding increasing concentrations (100 nM, 1 "M, 10 "M, 100 "M and 1 mM)
of each compound: NSC 69343, lanes 3-7; NSC 55636, lanes 8-12; NSC 123526, lanes
13-17; NSC 124808, lanes 18-22. Lane 1 shows the position of the full-length ds M13 DNA
marker (arrow) as detected by cybergold. Lane 2 is the control reaction containing DMSO,
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the solvent for each of the compounds. The position of greater than unit length products are
indicated by brackets.
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Figure 6.

Analogs of the indicated hit compounds that inhibit vaccinia DNA synthesis.
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Ratio of CC50 to IC50
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Concentration at which compound reduced plaques by 50%
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Concentration at which compound is 50% cytotoxic
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